Vorinostat (SAHA) in Uterine Sarcoma

Summary

Uterine sarcomas are rare tumors with a poor prognosis. The main purpose of this phase II proof-of-principle- pilot study is to test the efficacy of the hydroxamic acid-based Histone deacetylase inhibitor (HDACI) Vorinostat (SAHA) as monotherapy in patients with HDAC-positive, progressive, metastatic uterine sarcomas and mixed epithelial and mesenchymal tumors after prior anti-proliferative therapy.

Timeline

Start

2017-12-14

Primary completion

2019-02-04

Completion

2019-02-04

Outcome

Outcome not reported

Stopped (Enrollment): “The early termination was NOT due to safety reasons, terminated because of the very slow recruitment and problematic access to the study medication in Europe”

Drugs

Indications